AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
220.04
-0.04 (-0.02%)
At close: Jan 12, 2026, 4:00 PM EST
220.00
-0.04 (-0.02%)
After-hours: Jan 12, 2026, 7:58 PM EST
AbbVie Revenue
AbbVie had revenue of $15.78B in the quarter ending September 30, 2025, with 9.10% growth. This brings the company's revenue in the last twelve months to $59.64B, up 7.40% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$59.64B
Revenue Growth
+7.40%
P/S Ratio
6.53
Revenue / Employee
$1,084,436
Employees
55,000
Market Cap
388.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
| Dec 31, 2009 | 14.21B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
ABBV News
- 1 hour ago - AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices - WSJ
- 1 hour ago - Abbvie, US reach agreement to cut drug prices - Reuters
- 2 hours ago - AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans - PRNewsWire
- 12 hours ago - AbbVie, RemeGen partner on experimental solid tumor treatment - Reuters
- 13 hours ago - AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors - PRNewsWire
- 14 hours ago - AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States - PRNewsWire
- 14 hours ago - West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie - PRNewsWire
- 15 hours ago - Dividend Income: Lanny's November 2025 Summary - Seeking Alpha